Association between cumulative cisplatin dose and reproductive and sexual functions in patients with malignant ovarian germ cell tumors treated with bleomycin, etoposide, and cisplatin therapy: a case series study

Miki Akasaka1, Toshinori Hirai1, Kenta Yoshida2, Eiji Kondo2, Tomoaki Ikeda2 and Takuya Iwamoto1*

Abstract

Background: The impact of cumulative dose of cisplatin on gonadal function has not been clarified. We evaluated whether the cumulative cisplatin dose affects the resumption of menses in patients treated with bleomycin, etoposide, and cisplatin (BEP).

Main body: A case series study of women < 40 years with malignant ovarian germ cell tumors receiving BEP was conducted at Mie University Hospital. Using linear regression analysis, the correlation between the cumulative dose and resumption of menses was determined. Additionally, we compared the resumption of menses stratified by age (age < 20 years or ≥ 20 years). Ten women (median age: 20 [interquartile range: 15–26] years) have received a median of 4 cycles of BEP. The median period of resumption of menses was 5 months, which had no correlation with cumulative doses of bleomycin (143 mg/m² [71–220], y = -0.0069 x + 6.15, r = 0.19, P = 0.60), etoposide (1,533 mg/m² [900–2,000], y = 0.0004 x + 4.56, r = 0.08, P = 0.82), and cisplatin (363 mg/m² [225–400], y = 0.01 x + 1.67, r = 0.35, P = 0.32). Although the resumption of menses was comparable across ages, the cumulative doses of cisplatin were higher in patients aged < 20 years than in those aged ≥ 20 years (400 mg/m² [363–450] vs. 225 mg/m² [225–350], P = 0.02). Similarly, patients aged < 20 years had a higher cumulative etoposide dose than those aged ≥ 20 years (2,000 mg/m² [1,533–2,250] vs. 900 mg/m² [900–1,600], P = 0.03). Moreover, patients aged < 20 years received more cycles of BEP than those aged ≥ 20 years (4 cycles vs. 3 cycles, P = 0.03).

Short conclusion: All patients can recover menses after BEP, and the resumption of menses appeared at the median period of 5 months after BEP. The timing of menses resumption did not correlate with the cumulative doses of cisplatin.

Keywords: Fertility, Cancer, Cisplatin, Malignant ovarian germ cell tumor

Background

Malignant ovarian germ cell tumors (MOGCTs) are rare cancers that typically occur in young women [1]. Cisplatin-based chemotherapy, such as bleomycin, etoposide, and cisplatin (BEP), is an established regimen for MOGCTs, and with this treatment, more than 90% of
patients can survive for 5 years [2–4]. Previous studies have shown that more than 80% of women restarted regular menstruation following chemotherapy including BEP for MOGCTs [5, 6].

There was no dose–response between the likelihood of pregnancy and cisplatin dose in young women with cancers using a large dataset [7]. Guidelines have suggested that the gonadal toxicity of cisplatin varies according to the cisplatin dose in men [8–10]. Conversely, the European Society for Medical Oncology (ESMO) has reported that BEP or EP for women aged < 30 years is in the low-risk category (estimated risk is < 20%) of amenorrhea regardless of cisplatin dose, although this risk classification has not been established [10]. Therefore, it remains unclear about the dose–response association between cisplatin and gonadal toxicity before pregnancy. Since it was known that high rate of resumption of menses in patients with MOGCTs after chemotherapy, this study evaluated the timing of resumption of menses following BEP in addition to the rate of menstrual resumption in order to provide new information. This study also aimed to evaluate the association between cisplatin dose and gonadal function in female patients receiving BEP.

Main text
Patient data
A case series study was conducted at Mie University Hospital between January 2010 and May 2019. Eligibility criteria included patients (aged 10–40 years) who had a histological diagnosis of MOGCT. All patients underwent fertility-sparing surgeries. The exclusion criteria were as follows: (1) no record of menstrual history and (2) bilateral adnexectomy because of the difficulty of pregnancy. The study protocol was approved by the Institutional Review Board of Mie University Hospital (approval number: H2020-016). Clinical characteristics were obtained from electrical medical charts.

Throughout the diagnostic process, gynecologic pathologists diagnosed the histopathological category and classified it as MOGCT according to the World Health Organization classification criteria [11]. The clinical staging of ovarian cancer was determined based on the guidelines of the International Federation of Gynecology and Obstetrics (FIGO) 1988 from 2010 to 2014 [12] and FIGO 2014 from 2015 to 2019 [13]. In the following treatment step, all patients received BEP, which consists of bleomycin 30 units intravenously per week, etoposide 100 mg/m² intravenously (on days 1–5), and cisplatin 20 mg/m² intravenously (on days 1–5), lasted 21 days with 3–4 cycles as the standard schedule [8]. Furthermore, we included patients who received additional chemotherapy, vincristine, actinomycin D, and cyclophosphamide (VAC) because it remained unclear about the influence of additional cyclophosphamide on the resumption of menses in patients who received BEP. Cyclophosphamide is also reported to be at high risk of ovarian dysfunction [6].

The study outcome was defined as the period from the end of BEP to the resumption of menses. The obstetrician and gynecologist confirmed the resumption of menses during the medical interview.

Statistical analyses
Statistical analyses were performed using JMP® Pro 16 (SAS Institute Inc., Cary, NC, USA). Non-normal distributed continuous data are expressed as median (interquartile range [IQR]) and compared using the Mann–Whitney U test. Categorical data are expressed as numbers (%). A two-tailed P value < 0.05 was considered statistically significant. Linear regression analysis evaluated correlations between cumulative doses and outcome. Furthermore, primordial follicle counts decrease with advancing age [14]; therefore, we compared the relative dose intensity (RDI) and outcome by age groups (< 20 years and ≥ 20 years).

Results
Ten patients with MOGCT met the eligibility criteria. All patients underwent fertility-preserving surgical resection, and no recurrence of MOGCT was observed. The clinical characteristics are summarized in Table 1. The median age at the time of diagnosis was 20 years [15–26]. One patient was diagnosed with ovarian cancer during pregnancy, and the other patients were nullipara. Of the four patients who were married, there was only one patient who did not desire a child. In contrast, the others gave birth after the completion of chemotherapy.

In all patients, it took a median period of 5 months to recover menses after chemotherapy. Notably, one patient (No. 10) received an additional cycle of VAC regimen following BEP. In the VAC, doses of vinblastine, actinomycin D, and cyclophosphamide were 9.4 mg, 2 mg, and 1,100 mg, respectively. One patient (No 2.) was suspected of eruption due to bleomycin during the first cycle. Therefore, after the second cycle, the patient received etoposide and cisplatin, except for bleomycin. Two cases (No. 7 and No. 8) discontinued bleomycin due to febrile neutropenia and herpes zoster in the first cycle (day 15), and bleomycin was restarted from the second cycle. Additionally, one patient (No. 8) had an ovarian tumor during pregnancy, and she gave birth to a male infant via cesarean section at 28 weeks of gestation. She had no desire for additional childbearing after four cycles of BEP.

The cumulative doses for BEP did not correlate with outcome (Fig. 1A, r = 0.19, P = 0.60; Fig. 1B, r = 0.08, P = 0.82; Fig. 1C, r = 0.35, P = 0.32). Additionally, there
Table 1  Bleomycin, etoposide, and cisplatin (BEP) therapy and pregnancy status in fertility-preserved patients

| Age, y | Histology type/FIGO stage         | BSA, m² | Cumulative doses, mg/m² | Treatment cycle | Resumption of menses, M | Marital status | Live births |
|--------|----------------------------------|---------|-------------------------|-----------------|-------------------------|----------------|-------------|
|        |                                  |         | BLM | VP-16 | CDDP |                      |                |             |
| 1      | 22                               | Immature teratoma/Lc | 1.53 | 75     | 900   | 225 | 3 | 3 | Yes | 1 |
| 2      | 25                               | Immature teratoma/Lc | 1.37 | 25     | 900   | 225 | 3 | 5 | Yes | 1 |
| 3      | 25                               | Mixed germ cell tumor/IIIb | 1.53 | 100    | 1,200 | 300 | 4 | 6 | Yes | 2 |
| 4      | 16                               | Dysgerminoma/IIIc | 1.57 | 185    | 1,625 | 325 | 6 | 2 | No  | - |
| 5      | 29                               | Yolk sac tumor/Lc | 1.66 | 75     | 900   | 225 | 3 | 3 | No  | - |
| 6      | 14                               | Yolk sac tumor/Lc | 1.42 | 210    | 2,500 | 500 | 5 | 4 | No  | - |
| 7      | 18                               | Immature teratoma/La | 1.49 | 220    | 2,000 | 400 | 4 | 5 | No  | - |
| 8      | 27                               | Yolk sac tumor/IIIc | 1.38 | 220    | 2,000 | 400 | 4 | 5 | Yes | - |
| 9      | 15                               | Immature teratoma/La | 1.39 | 220    | 2,000 | 400 | 4 | 7 | No  | - |
| 10     | 10                               | Immature teratoma/IIIc | 1.24 | 60     | 1,440 | 400 | 4 | 12 | No  | - |
|        | 20 (15–26)                       |         | 1.5 (1.4–1.5) | 143 (71–220) | 1,533 (900–2,000) | 363 (225–400) | 4 (3–4) | 5 (3–6) | - | - |

Continuous data are expressed as median (interquartile range)

Live births are expressed as the number after BEP therapy

Patient No. 10 received a total of 1 cycle of vinblastine, actinomycin D, and cyclophosphamide therapy following BEP therapy. Patient No. 8 had a history of pregnancy before BEP therapy, and she had no desire for additional childbearing after 4 cycles of BEP therapy.

y Year, M Months, BSA Body surface area, FIGO International Federation of Gynecology and Obstetrics, BLM Bleomycin, VP-16 Etoposide, CDDP Cisplatin
Fig. 1  Association between cumulative doses of anticancer drugs and timing of resumption of menses. The X-axis and Y-axis represent the cumulative bleomycin (a), etoposide (b), and cisplatin (c) dose and the timing of resumption of menses, respectively. Open circles represent age < 20 years. Closed circles represent age ≥ 20 years. Gray points represent duplicated points (age 18 and 27 years). a: This point is duplicated in two patients (aged 22 years and 29 years). b: This point corresponds to a patient treated with vinblastine, actinomycin D, and cyclophosphamide (VAC) in addition to bleomycin, etoposide, and cisplatin (BEP)
was no significant difference in the timing of resumption of menses between patients aged < 20 years and ≥ 20 years (5 months [3–10] vs. 5 months [3–6], \( P = 0.40 \)). Conversely, patients aged < 20 years received more cycles of BEP than those aged ≥ 20 years (4 cycles [4–6] vs. 3 cycles [3, 4], \( P = 0.03 \)). There was no difference in RDI (%) for each drug across age groups (Additional file 1).

**Discussion**

Our study revealed that all patients recovered, and the resumption of menses appeared at a median period of 5 months after BEP. Additionally, three of the four married patients gave birth after the completion of BEP. These results are supported by the statement that BEP for female patients aged < 30 years is in the low-risk category of amenorrhea regardless of cisplatin dose [10]. Tamauchi et al. also showed that 42 of the 45 MOGCT survivors became pregnant and 40 successfully gave birth. Of these 40 patients, 50% had received BEP; however, the cumulative dose of anticancer drugs and the timing of menstrual resumption were unknown [15]. In previous reports, more than 80% of the patients resumed menstruation following cisplatin-based chemotherapy including BEP for MOGCTs [5, 6], which discord with our findings. Conversely, Pektasides et al. showed patients largely restarted the resumption of menses under POMB/ACE regimen (cisplatin, vincristine, methotrexate, bleomycin/actinomycin D, cyclophosphamide, etoposide) with the resumption of menses of 4.5 months after chemotherapy [16], which is consistent with our findings. This difference might be attributed to details of chemotherapy although information from previous studies is lacking.

Our result revealed no correlation between cumulative cisplatin dose and resumption of menses under standard treatment cycles. Satoh et al. reported that most patients aged < 40 years who received BEP at 20 mg/m^2/day of cisplatin on days 1–5 recovered menstruation [17]. Thus, the standard treatment intensity of cisplatin can maintain reproductive function in patients with MOGCT. In our study, no effect of age on the timing of menstrual resumption was identified. On the other hand, it was observed that the patients aged < 20 years received more intensified BEP than those aged ≥ 20 years. The ovarian function is relatively high in young patients [15]. Accordingly, young patients can tolerate gonadal toxicity against the intensified BEP. There was an insignificant difference in the resumption of menses comparing patients < 20 years to those ≥ 20 years, suggesting that younger age groups have better tolerance for gonadal toxicity. The association between cumulative dose of cisplatin and the timing of resumption of menses in under 30 years old should be future topic to be considered.

One patient (No. 10) experienced relatively long-term amenorrhea due to cyclophosphamide, corresponded to a high risk of amenorrhea. Notably, she received BEP with a similar intensity compared to the other patients. The ESMO guidelines suggest that even in Ewing’s sarcoma, female patients (< 35 years) had a low-risk of amenorrhea against multi-agent chemotherapy including cyclophosphamide [10]. However, cyclophosphamide certainly decreases gonadal function [8]. Similarly, a single cycle of cyclophosphamide (890 mg/m^2) prolonged the resumption of menses in the patient. Close attention should be paid to the cyclophosphamide-based regimen.

This study has some limitations in interpreting the results. First, this study included a small number of patients. Second, this study was a retrospective design, we could not confirm the causality of chemotherapy and amenorrhea in detail. Third, the study patients aged < 30 years, and our results cannot be extrapolated to older patients who desire childbearing. Fourth, we did not collect the serum levels of anti-Müllerian hormone, a surrogate marker of sexual function [18].

**Conclusions**

In summary, all patients with a standard intensity of BEP were able to resume menses at a median of 5 months.

The timing of menses resumption did not correlate with the cumulative doses of cisplatin. This information will be useful in educating patients prior to starting chemotherapy.

**Abbreviations**

BEP: Bleomycin, etoposide, and cisplatin; MOGCTs: Malignant ovarian germ cell tumors; ESMO: The European Society for Medical Oncology; FIGO: The International Federation of Gynecology and Obstetrics; VAC: Vincristine, actinomycin D, and cyclophosphamide; RDI: Relative dose intensity.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40780-022-00265-8.

**Acknowledgements**

None.

**Authors’ contributions**

MA contributed to the study design, data acquisition, statistical analysis, and preparing the manuscript. TH contributed to the statistical analysis and preparing the manuscript. KY, EK, and TI contributed to data collection. TI supervised this study. All authors read and approved the final manuscript.

**Funding**

Not applicable.
Availability of data and materials
All the data generated or analyzed in this study are included in the published article.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pharmacy, Mie University Hospital, 2-174, Edobashi, Tsu, Mie 514-8507, Japan. 2 Department of Obstetrics and Gynecology, Mie University Hospital, 2-174, Edobashi, Tsu, Mie 514-8507, Japan.

Received: 24 May 2022   Accepted: 7 November 2022
Published online: 17 November 2022

References
1. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol. 2005;97:519–23.
2. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors. Gynecol Oncol. 2015;137:418–22.
3. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993;11:598–606.
4. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997;15:1844–52.
5. Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer. 2000;89:391–8.
6. Low JJ, Ilancheran A, Ng JS. Malignant ovarian germ-cell tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26:347–55.
7. Choy EJ, Stratton KL, Leisenring WM, Oeffinger KC, Sklar CA, Donaldson SS, et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016;17:567–76.
8. NCCN Clinical Practice Guidelines in Oncology (Ovarian Cancer Fallopian Tube Cancer/Primary Peritoneal Cancer). https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 10 May 2022.
9. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–31.
10. Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukemborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines(†). Ann Oncol. 2020;31:1664–79.
11. Kurman RJ, Aaronson N. WHO classification of tumours of female reproductive organs. 2014. p. 119–43.
12. Kandukuri SR, Rao J. FIGO 2013 staging system for ovarian cancer: what is new in comparison to the 1988 staging system? Curr Opin Obstet Gynecol. 2015;27:48–52.
13. Kurman RJ. Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication of Guidelines From the International Federation of Gynecology and Obstetrics (FIGO). Obstet Gynecol. 2015;126:171–4.
14. Oktay O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110:2222–9.
15. Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, et al. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol. 2018;219:385 e1–e7.
16. Pektasides D, Rustin GJ, Newlands ES, Beggant RH, Bagshawe KD. Fertility after chemotherapy for ovarian germ cell tumours. Br J Obstet Gynaecol. 1987;94:477–9.
17. Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y, et al. Administration of standard-dose BEP regimen (bleomycin + etoposide + cisplatin) is essential for treatment of ovarian yolk sac tumour. Eur J Cancer. 2015;51:340–51.
18. Ledger WL. Clinical utility of measurement of anti-mullerian hormone in reproductive endocrinology. J Clin Endocrinol Metab. 2010;95:1444–54.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions